TYR and neoplasm: The rapid development of immunotherapy and targeted therapy in recent years provides a basis for the newly explored triple therapy regimen (immune checkpoint inhibitor + tyrosinase inhibitor + chemotherapy) to significantly improve tumor treatment efficacy and conversion rate (16).